A six-year evaluation of antibiotics consumption in the defined daily doses in the septic orthopedic-traumatology department by Bernaz, E. P.
RESEARCH STUDIES
10
Curierul medical, December 2015, Vol. 58, No 6
A six-year evaluation of antibiotics consumption in the defined daily doses 
in the septic orthopedic-traumotology department
E. P. Bernaz
Business Administration Office, Emergency Medicine Institute, Chisinau, the Republic of Moldova
Corresponding author: bernaz_e@yahoo.com. Received October 26, 2015; accepted December 12, 2015
Abstract
Background: Septic orthopedic and traumatology treatment permanently required a great spectrum of antibiotics to be used. Evaluation of consumption 
in defined daily doses is one of principal methods for improving rational usage and good planning of hospitals’ necessities of antiinfectives for systemic use.
Material and methods: For this study we used data of a six-year (2009-2014) period, in septic orthopedic-traumotology department of the Emergency 
Medicine Institute, which show the consumption dynamics of anti-infectives for systemic use of drugs in grams and value indexes.
Results: The defined daily doses (DDD)/1000 occupied-bed days (OBD) of antibiotics in septic orthopedic-traumotology department from 578 in 2009 
increased to 675 in 2014 or by 16.78% and is 14.05% lower than medium consumption of 769.83 in 152 international hospitals with the similar activity. 
The value of 5741 lei per DDD/1000 OBD in 2009 recorded a slow decline to 5447 lei or by 5.12%. The cost of one medium DDD from 9.94 lei in 2009 
decreased to 8.07 lei in 2014 or 18.81%. The rate of anti-infectives for systemic use in 2014 presented 50169.00 lei or a share of 32% from the total 
departmental value of consumption; the same data in 2009 were 78054.84 lei or 34.75%. The share from the total antibiotics institutional consumption 
in 2014 was recorded 3.34% and 5.00% in 2009 respectively. The average antibiotics annual institution consumption constituting 464.1 in 2014 is higher 
by 1.06% comparatively with medium consumption of 459.20 registered in 1706 international hospitals, and by 35.31% in comparison with global 
consumption of 343 defined daily doses per 1000 patient-days.
Conclusions: The increase of DDD/1000 OBD took place as a result of worldwide increasing pathogenic microbes resistance to antibiotics. Nevertheless, 
decrease value indexes and cost of one DDD show in the best way the capacity of departmental management to cope with institutional budget deficiency 
and maintain qualitative antimicrobial treatment of hospitalized patients.
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Introduction
“The doorstep to the temple of wisdom is knowledge of 
our own ignorance” – Benjamin Franklin. The battle against 
infection is as old as human civilization. During the last few 
centuries, great scholars such as Louis Pasteur, Ignaz Philipp 
Semmelweis, Alexander Fleming, and Joseph Lister have 
transformed the practice of medicine through their extra-
ordinary discoveries. Despite the progress made and strides 
gained, our mission to prevent infection following surgery 
remains unaccomplished. It is not an exaggeration to claim 
that fear of infection lives in the heart of every surgeon who 
steps into the operating room daily [1]. Septic orthopedic and 
traumatology treatment permanently requires a great spec-
trum of antibiotics to be used. Evaluation of consumption in 
defined daily doses is one of principal methods for improving 
rational usage and good planning of hospitals necessities of 
anti-infectives for systemic use.
The World Health Organization "European strategic acti-
on plan on antibiotic resistance 2011–2016" mentioned that 
"Antimicrobial resistance is not a new phenomenon, but it 
is increasing and new resistant strains continue to emerge”. 
One of the main aims of the plan includes to promote prudent 
use of antibiotics and other drugs [2]. An important source 
of information is “DRUG CONSUMPTION DATABASES 
IN EUROPE” published by a European Consortium in 2015 
[3]. We must recognize that in the Republic of Moldova drugs 
consumption analysis in defined daily doses (DDD) per 1000 
occupied-bed days (OBD), DDD/1000), as an important in-
dicator for optimization of rational use of drug remedies in 
hospitals as all and the society are not addressed enough and 
highlighted by scientific research literature.
The primary aim of the study was to evaluate institutional 
representative data on antibiotics’ utilization in accordance 
with World Health Organization (WHO) requirements, for 
six-year (2009-2014) period in septic orthopedic and trau-
matology institutional department, and to determine value 
of DDD/1000. Based on the obtained data, it aimed to make 
conclusions on the use of anti-infectives for systemic use in 
department and to propose recommendations for ensuring 
their optimization.
Emergency Medicine Institute of the Republic of Moldova 
(EMI) was founded in 1959. EMI consists of 9 clinical services 
with 600 beds overall including orthopedic-traumatology for 
150 beds, municipal center with 8 seats of hemodialysis and 
9 beds. There are 4 outpatient departments of traumatology 
and orthopedics as well [4].
Material and methods
For this study we used the data of a six-year (2009-2014) 
period, in septic orthopedic-traumotology department of EMI 
for 40 beds, which show the dynamics of consumption of anti-
infectives for systemic use drugs, as classified by Anatomical 
Therapeutic Chemical (ATC), classification system of World 
Health Organization indicated in grams and value indexes. 
Statistical, analytical, mathematical, compararative, logical 
and descriptive were used as the methods of study.
Results and discussion
Total institutional antibiotic consumption in value 
indexes was 1562575 lei in 2009 and 1500888 lei in 2014 
that represents respectively 17% and 14% from the whole 
amount of drugs [5]. 
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In figure 1 it is shown the consumption rate of anti-
infectives for systemic use in lei in comparison with other 
pharmacotherapeutic groups in orthopedic-traumatology 
department in 2014.
As can be observed the rate of anti-infectives for systemic 
use present 50169.00 lei or a share of 32% from the total value 
amount of 156821 lei drugs consumption in 2014. In 2009 the 
same data were 78054.84 lei or 34.75% from total of 224644 
lei. The share of departmental from the total antibiotics in-
stitutional consumption in 2014 recorded 3.34% and 5.00% 
in 2009 respectively. 
For evaluating the consumption of anti-infectives for 
systemic use drugs in the department during 2009-2014 were 
followed 10 steps of determining DDD/1000 [6, 7, 8] and the 
statistics data concerning the number of treated patients (for 
only patients with health insurance and other free treated by 
the state categories of citizens), the number of bed/days (2009 
=10664; 2010 = 10017; 2011 = 9540; 2012 = 10178; 2013 = 
9701; 2014 = 9535) and data about total annual consumption 
of antibiotics were used.
All in all 48 antimicrobial remedies (both for parenteral 
and enteral use) for treating assistance of hospitalized pati-
ents in the evaluated period were used, from which with only 
enteral form 22 names, with only parenteral form 26 names 
and with both forms 10 names, which represents 37 active 
antimicrobial substances.
Parenteral forms consumption rate of antibiotic subgroups 
evaluated in DDD/1000 during 2009-2014 is shown in figure2.
As can be observed from figure 2 in the evaluated 
period the average consumption annual rate of all antibi-
otic subgroups records a decline from 543 in 2009 to 490 
DDD/1000 in 2014 or by 9.76%. The main consumption 
of 461.65 DDD/1000 or 85.02% from the total in 2009 to 
458.41 or 93.55% in 2014 with a slow decrease of 0.70% 
during mentioned years was registered for aminoglyco-
side antibacterials (Streptomycinum 1.0, Gentamycinum 
0.2, Kanamycinum 1.0, Amikacinum 1.0), other beta-lac-
tam antibacterials (Cefazolinum 3.0, Cefuroximum 3.0, 
Cefotaximum4.0, Ceftazidimum 4.0, Ceftriaxonum 2.0, 
Cefoperazonum 4.0) and macrolides, lincosamides and 
streptogramins (Clarithromycinum 0.5, Azithromycinum 
0.5, Lincomycinum 1.8).
In figure 3 consumption rate of enteral forms of anti-
bacterials for systemic use subgroups in DDD/1000 during 
2009-2014 is shown.
As it is seen from figure 2 the average consumption annual 
rate of antibiotics for oral usage increased from 35 in 2009 to 
185 DDD/1000 OBD in 2014 or by 5.29 times. The highest 
consumption from 19.4 DDD/1000 or 55.43% of the total in 
2009 to 169.9 or 91.84% of the total in 2014 and an increase 
by 8.76 times during the evaluated period was registered for 
quinolone antibacterials (Gatifloxacinum 0.4, Acidum pipe-
midicum 0.8),other beta-lactam antibacterials (Cefalexinum 
2.0, Cefuroximum 0.5, Cefaclorum 1.0 gram and Cefixim 0.4) 
and beta-lactam antibacterials, penicillins.
In figure 4 the total (parenteral and enteral forms) antibi-
otic subgroups used rates are demonstrated. 
Fig. 1. Comparative share of anti-infectives for systemic use and 
other pharmacotherapeutic groups from total consumption.
Fig. 2. Parenteral forms of consumption of antibacterials  
for systemic use in DDD/1000.
Fig.3. Enteral forms of consumption of antibacterials 
for systemic use in DDD/1000.
Fig. 4. The total consumption of antibacterials  
for systemic use in DDD/1000.
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Table 1
The ratio between DDD/1000 for parenteral to enteral forms of antibiotics and percentage from the total
The ratio DDD/1000 of parenteral to enteral use and percentage from the total
Years 2009 2 010 2011 2012 2013 2014
Parenteral 543 709 576 371 590 490
Enteral 35 78 191 108 67 185
The ratio of parenteral to oral 15.74 9.09 3.02 3.43 8.81 2.65
Total 578 788 767 479 657 675
Percentage from total
Parenteral 93.94% 89.97% 75.10% 77.45% 89.80% 72.59%
Enteral 6.06% 9.90% 24.90% 22.55% 10.20% 27.41%
As it can be observed from figure 3 the average aggregated 
annual rate for total antibiotics consumption in the evaluated 
period increased from 578 in 2009 to 675 DDD/1000 in 2014 
or by 16.78%.
The first 4 subgroups with the highest yearly consumpti-
on from 451,97 DDD/1000 or 78.20% of the total in 2009 to 
575,42 DDD/1000 or 85.20% of the total in 2014 respectively 
and an increase of 27.31% during the evaluated period were 
registered for other beta-lactam antibacterials, aminoglyco-
side antibacterials, beta-lactam antibacterials, penicillins.
In table 1 the ratio DDD/1000 of parenteral to enteral use 
forms and percentage from the total is shown.
From table 1 it can be seen that in the evaluated period 
the ratio between antibiotics DDD/1000 parenteral to enteral 
forms decreased from 15.74 to 2.65 times. The percentage 
of parenteral forms from the total antibiotics DDD/1000 
decreased from 93.94% in 2009 to 72.59% in 2014 and vice 
versa enteral forms increased the ratio from 6.06% to 27.41% 
respectively. Similar data for the entire institution were pu-
blished early [9].
 Comparison of total consumption data of anti-infectives 
for systemic use evaluated in DDD among 1576 European 
hospitals and surgeries, orthopedics and traumotplogy de-
partments with the similar data of EMI and department is 
presented in figure 2.
As we can see from table 2 the average annual rate 
for total-hospital antibiotics utilization period in EMI 
decreased from 662.4 in 2009 to 464.1 DDD/1000 in 2014 
or by 30%. That result was higher by 67.65 DDD/1000 
or by 14.58% than the medium consumption of 396.45 
DDD/1000 registered in case of 1256 international hospitals 
[(1115x393 + 34x395 + 43x422 + 55x448 + 1x400 + 1x403 + 
7x390):1256] and lower by 112.66 DDD/1000 or by 36.68% 
in case of 450 international hospitals where the mentioned 
medium was 634.34 DDD/1000 [(8x601 + 54x547 + 1x595 
+ 40x499 + 195x583 + 7x570 + 7x1610+ 8x724 +776x130) 
: 450] respectivly.
Other all medium consumption in 1706 (1256+450) in-
ternational hospitals constituing 459.20 DDD/1000 was lower 
than consumption of 464.1 DDD/1000 in EMI in 2014 by 4.90 
DDD/1000 or by 1.06% and lower by 121.1 comparatively to 
global antibiotic consumption of 343 defined daily doses per 
1000 patient-days or by 20.09%.
In septic orthopedic-traumotology department of EMI in 
the evaluated period was registered an increase from 578 in 
2009 to 675 DDD/1000 in 2014 respectively or by 16.78%. In 
case of 152 international hospitals with similar surgery and 
orthopedic-traumotology activities medium consumption was 
(8x793 + 7x570 + 8x724 + 776x130) : 152= 769.83 DDD/1000, 
that was by 94.83 DDD/1000 more than results recorded in 
EMI in 2014 or by 14.05%. 
In figure 5 the total consumption of other beta-lactam 
antibacterials for parenteral and enteral use in DDD/1000 is 
demonstrated.
From this chart as one can see in the evaluated period 
the total consumption of parenteral and enteral forms 
of cephalosporin’s G-I (Cefalexinum and Cefazolinum) 
decreased slowly from 137.83 to 130.68 or by 5.20%, 
cephalosporin’s G-II (Cefuroximum, Cefaclorum) and G-
III (Cefotaximum, Ceftazidimum, Ceftriaxonum, Cefixim, 
Cefoperazonum, Cefoperazonum + Sulbactamum) demons-
trate a considerable increment of consumption from 29.29 
(16.25+13.04) in 2009 to 145.15 DDD/1000(39.64+105.5) 
or by 4.85 times, cephalosporins G-IV and carbapemens 
(Meropenemum, Imipenemum+Cilastatinum) had a 
low consumption only during 2010 to 2014. The total 
consumption of other beta-lactam antibacterials shows a 
considerable increment from 167 to 276 DDD/1000 or by 
65.27%. It can be mentioned a visible decrement of con-
sumption of cephalosporin’s G-I with parenteral forms from 
136.92 DDD/1000 in 2009 to 70.56 in 2014 or by 48.47% 
and vice versa a considerable growth of consumption of 
cephalosporin’s G-I with enteral use forms from 0.93 in 
2009 to 70.1 in 2014 or by 75.38 times. Similar data for the 
entire institution were published early [23].
The cost of DDD/1000 in lei for parenteral forms of 
antibacterials for systemc use during 2009-2014 is shown in 
figure 6.Fig. 5. Total consumption of J01D other beta-lactam 
antibacterials for parenteral and enteral use in DDD/1000.
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Table 2
Surveillance studies of antibiotic use in international hospitals  
in comparison with the similar data in Emergency Medicine Institute and department
Setting Surveillance  time-period Data source
Frequency  
of data  
collection
Use of antibiotics in DDD/1000  
bed-days over the study period
Emergency Medicine Institute 6 years (2009– 2014)
Pharmacy  
dispensing 
records (PDR)
Annual 662.4, hospital-wide in 2009;  464.1, hospital-wide in 2014
Septic orthopedic-traumotology  
department of EMI 6 years (2009–2014) (PDR) Annual
578, department-wide in 2009; 
675, department-wide in 2014.
1115 hospitals in France [10] 3 years (2008–2010) (PDR) Annual 370.0, hospital-wide in 2008;393.0, hospital-wide in 2010.
34 public hospitals and 43 private hospi-
tals located in south-western France [11] 2005 (PDR) Annual
395, hospital-wide;
422, hospital-wide.
49-59 hospitals in the Netherlands [12]
medium 54 hospitals 5 years (1997–2001) (PDR) Annual
472.0, hospital-wide in 1997; 
547.0, hospital-wide in 2001.
55 public hospitals in Denmark [13] 5 years (1997–2001) Danish Medicines Agency Annual
380.0, hospital-wide in 1997; 
448.0, hospital-wide in 2001.
1 university hospital in Switzerland [14] 5 years (1996–2000) (PDR) Not specified 400.0, hospital-wide; 
Military Medical Academy,  
Sofia, Bulgaria [15] 1 year (2011) (PDR) Annual 403.0, hospital-wide.
1 general hospital in Spain [16] 5 years (1996–2000) (PDR) Annual 595.0, hospital-wide.
8 university hospitals in Germany [17] 3 years (1998–2000) (PDR) Annual 601.0, medical wards; 793.0, surgical wards.
40 non-university regional acute care ge-
neral hospitals in south-western Germany, 
2001-2002 [18]
2 years (2001–2002) (PDR) Annual 499.0, with a mean in internal medicine;434.0, with a mean in surgery.
530 French hospitals in 2007 from which 
195 in general hospitals and 357 for hospi-
tals detailed clinical surgery activity [19]
1 year (2007) (PDR) Annual 557.0, in medicine;553.0, in surgery.
7 hospitals in Stockholm [20] 1 year (2000) (PDR) Annual 390 to 570 internal medicine;1020 to 1610 infectious disease.
8 Norwegian hospitals serving 36% of the 
nation’s population [21]
from 
2002 to
2007
(PDR) Annual increased from 617 to724 DDDs/1000 bed-days.
130 US hospitals[22] August 20021–31 July 2003 (PDR) Annual
792
776
The global antibiotic consumption [23] varied little between 2006 and 2008 (PDR) Annual
343 defined daily doses (DDD)  
per 1000 patient-days (PD).
Fig. 6. The cost of parenteral forms of antibacterials  
for systemic use per DDD/1000 in lei.
As we can see from figure 5 the average consumption an-
nual rate per DDD/1000 in value indexes (lei) of all parenteral 
antibiotic subgroups records a decline from 5563 in 2009 to 
4778 lei in 2014 or by 14.11%. The medium yearly consump-
tion for the evaluated period with more than 1000 lei per 
DDD/1000 was registered for other beta-lactam antibacterials 
(3735.62 leis) and for beta-lactam antibacterials (1358.73 lei), 
more than 500 lei recorded aminoglycoside antibacterials 
(838.3 lei). Other subgrups as other antibacterials, macrolides, 
lincosamides and streptogramins, quinolone antibacterials, 
antimycotics for systemic use registered less than 500 leis 
per DDD/1000.
Consumption rate in value indexes in lei for enteral forms 
of antibiotics subgroups per DDD/1000 during 2009-2014 is 
shown in figure 7.
From figure 7 it can be found that the average con-
sumption annual rate in value indexes of all antibiotic 
subgroups records an increase from 177 in 2009 to 669 
lei per DDD/1000 in 2014 or by 3.78 times. The medium 
yearly consumption for the evaluated period with more 
than 100 lei per DDD/1000 was registered for beta-lactam 
antibacterials, penicillins, other beta-lactam antibacterials 
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and antimycotics for systemic use. All other subgroups 
recorded a consumption from 3 to 51 DDD/1000.
Consumption rate in value indexes (lei) of parenteral and 
enteral forms of antibiotics subgroups in DDD/1000 during 
2009-2014 is shown in figure 8.
In this chart the presented data demonstrate that the ave-
rage consumption annual rate in value indexes (lei) of total 
antibiotics record a decline from 5741 in 2009 to 5447 lei per 
DDD/1000 in 2014 or by 5.12%. The medium yearly cost of 
DDD/1000 was registered more than: 3000 lei for other beta-
lactam antibacterials, 1500 lei for beta-lactam antibacterials, 
penicillins, 500 lei for aminoglycoside antibacterials, between 
100 – 500 lei for macrolides, lincosamides and streptogramins, 
quinolone antibacterials, other antibacterials and antimycotics 
for systemic use, and between 2 – 20 lei for tetracyclines and 
amphenicols.
Fig. 7. The cost in lei for enteral forms of antibacterials  
for systemc use per DDD/1000.
Fig. 8. Total cost of antibacterials for systemc  
use per DDD/1000 in lei.
Table 3
Cost of one medium DDD antibacterial for systemic use of parenteral, enteral forms and total in lei
Septic orthopedic-traumatology department
Data for determining and cost of 1(one) DDD 2009 2010 2011 2012 2013 2014
Parenteral cost (lei) DDD/1000 5563.38 11930.48 7039.12 5616.86 6583.6 4778
Enteral cost (lei) DDD/1000 177.27 327.53 519.6 528.1 615.67 669.24
Total (Parenteral and enteral cost (lei) DDD/1000) 5741 12258 7558 6145 7199 5447
Parenteral DDD/1000 543.12 709.39 576.33 371.17 590.46 490.06
Enteral DDD/1000 34.5 78.07 190.67 108.17 67 185.21
Total (Parenteral and enteral DDD/1000) 577.62 787.46 767 479.34 657.46 675.27
Total (Parenteral and enteral cost (lei) 1 (one) DDD) 9.94 15.57 9.85 12.82 10.95 8.07
Parenteral cost (lei) 1 (one)DDD 10.24 16.82 12.21 15.13 11.15 9.75
Enteral cost (lei) 1(one) DDD 5.14 4.20 2.73 4.88 9.19 3.61
Table 4
The medium cost per one DDD in lei of other beta-lactamantibacterials for parenteral and enteral forms and total
Septic orthopedic-traumotology department 
Data for determining and cost of 1(one) DDD 2009 2010 2011 2012 2013 2014
Parenteral cost (lei) DDD/1000 3174.22 7974.98 2012.62 2328.99 3662.1 3260.84
Enteral cost (lei) DDD/1000 3.02 2.88 16.52 114.6 211.81 329.52
Parenteral and enteral cost (lei) DDD/1000 3177.24 7977.86 2029.14 2443.59 3873.9 3590.4
Parenteral DDD/1000 166.21 387.24 70.55 245.24 198.74 214.89
Enteral DDD/1000 0.93 0 7.44 19.73 21.65 61.25
Parenteral and enteral DDD/1000 167.14 387.24 77.99 254.57 220.39 276.14
Total (Parenteral and enteral cost (lei) 1 (one) DDD) 19.01 20.60 26.02 9.60 17.58 13.00
Parenteral cost (lei) 1 (one) DDD 19.10 20.59 28.53 9.50 18.43 15.17
Enteral cost (lei) 1 (one) DDD 3.25 0.00 2.22 5.81 9.78 5.38
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To determine the cost of one medium DDD of antibac-
terials for systemic use separately for parenteral and enteral 
pharmaceutical forms were divided by the cost of DDD/1000 
to DDD/1000 respectively. The cost of one medium DDD 
antibiotics in lei for parenteral and enteral forms and total is 
shown in table 3 and 4.
As we can see from table 3 in the evaluated period the cost 
of one medium DDD decreased from 10.24 lei in 2009 to 9.75 
lei in 2014 or by 4.79% for parenteral forms, from 5.14 to 3.61 
lei or by 29.77% for enteral forms and from 9.94 to 8.07 lei or 
by 18.81% for one total DDD.
In chronological way for the evaluated years the ratio be-
tween the cost of one medium DDD of parenteral and enteral 
forms was respectively 1.99:1; 4:1; 4.47:1; 3.1:1; 1.2:1 and 2.7:1.
Calculation of the cost in lei per one medium DDD for 
parenteral, enteral forms and total for other beta-lactam anti-
bacterials is shown in table 4. As we can see from this table in 
the evaluated period total cost of one medium DDD decreased 
from 19.01 in 2009 to 13.00 leis in 2014 or by 31.94%, for pa-
renteral from 19.10 to 15.17 lei or by 20.58% and for enteral 
use increased from 3.32 to 5.38 lei or by 59.64%.
The ratio between the cost of parenteral and enteral forms 
per one medium DDD in the evaluated years was respectivly 
5.88:1; 20:1; 12.87:1; 1.64:1; 1.88:1 and 2:82:1.
Conclusions
1. DDD/1000 OBD in the septic orthopedic-traumotology 
department from 578 in 2009 increased to 675 in 2014 or by 
16.78% of which other beta-lactam antibacterials from 167 or 
28.89% and 276 or 40.89% respectively. The consumption of 
parenteral forms constituing 543 DDD/1000 or 93.95% from 
the total in 2009 decreased to 490 DDD/1000 OBD or by 9.76% 
in 2014 and vice versa use of enteral forms constituing 35 or 
6.06% from the total in 2009, increased to 185 DDD/1000 
OBD in 2014 or by 5.29 times respectively. 
2. The cost of 5741 lei per DDD/1000 OBD in 2009 re-
corded a slow decline to 5447 lei or by 5.12%. The cost of one 
medium DDD from 9.94 lei in 2009 decreased to 8.07 lei in 
2014 or by 18.81%. The rate of anti-infectives for systemic use 
in 2014 presented 50169.00 lei or a share of 32% from the total 
departmental value consumption; the same data in 2009 were 
78054.84 lei or 34.75%. The share from the total antibiotics 
institutional consumption in 2014 recorded 3.34% and 5.00% 
in 2009 respectively. 
3. The average annual rate for total-institution antibiotics 
utilization period in EMI decreased from 662.4 in 2009 to 
464.1 DDD/1000 OBD in 2014 or by 30%. Obtained record is 
higher by 6.69% comparatively with medium consumption of 
433.06 DDD/1000 registered in 1576 international hospitals, 
and by 35.31% than global antibiotic consumption of 343 
defined daily doses per 1000 patient-days. 
4. There were evaluated 48 antimicrobial remedies (both 
for parenteral and enteral use) for hospitalized patients, from 
which with only enteral form 22 names, with only parenteral 
form 26 names and with both forms 10 names, which represent 
37 active antimicrobial substances. 
5. The ratio between the cost of one medium DDD of 
parenteral and enteral forms of antibacterials for systemic 
use was 1.99:1; 4:1; 4.47:1; 3.1:1; 1.2:1 and 2.7:1 for the eva-
luated years. For other beta-lactam antibacterials this ratio 
was 5.88:1; 20:1; 12.87:1; 1.64:1; 1.88:1 and 2:82:1 respectivly.
6. The increase of DDD/1000 OBD during the evaluated 
period took place as a result of worldwide increasing pathoge-
nic microbes’ resistance to antibiotics. Nevertheless, decrease 
value indexes and cost of one DDD show in the best way the 
capacity of departmental management to cope with instituti-
onal budget deficiency and maintain qualitative antimicrobial 
treatment of hospitalized patients. 
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